California State Teachers Retirement System lowered its stake in shares of CytRx Corp. (NASDAQ:CYTR) by 1.0% during the second quarter, Holdings Channel reports. The firm owned 140,074 shares of the company’s stock after selling 1,400 shares during the period. California State Teachers Retirement System owned about 0.21% of CytRx Corp. worth $312,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in CYTR. Metropolitan Life Insurance Co. NY bought a new stake in CytRx Corp. during the first quarter worth approximately $155,000. Geode Capital Management LLC increased its stake in CytRx Corp. by 0.8% in the first quarter. Geode Capital Management LLC now owns 351,694 shares of the company’s stock worth $942,000 after buying an additional 2,958 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in shares of CytRx Corp. by 0.4% in the second quarter. Bank of New York Mellon Corp now owns 201,596 shares of the company’s stock valued at $450,000 after buying an additional 725 shares in the last quarter. 19.70% of the stock is owned by institutional investors.
CytRx Corp. (NASDAQ:CYTR) traded down 0.9640% on Monday, hitting $0.4623. 465,793 shares of the company were exchanged. CytRx Corp. has a 52 week low of $0.45 and a 52 week high of $3.66. The firm’s 50 day moving average is $0.57 and its 200 day moving average is $1.70. The company’s market capitalization is $44.82 million.
CytRx Corp. (NASDAQ:CYTR) last posted its earnings results on Friday, July 29th. The company reported ($0.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by $0.08. On average, equities research analysts forecast that CytRx Corp. will post ($0.71) earnings per share for the current fiscal year.
Several research analysts have recently weighed in on CYTR shares. Zacks Investment Research upgraded shares of CytRx Corp. from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a research note on Tuesday, September 6th. FBR & Co dropped their price target on shares of CytRx Corp. from $8.00 to $3.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 12th. Jefferies Group reiterated a “hold” rating and set a $0.75 price target (down previously from $2.50) on shares of CytRx Corp. in a research note on Friday, July 15th. Finally, S&P Equity Research dropped their price target on shares of CytRx Corp. from $1.04 to $0.75 in a research note on Tuesday, July 12th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $5.32.
About CytRx Corp.
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy.
Want to see what other hedge funds are holding CYTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytRx Corp. (NASDAQ:CYTR).
Receive News & Ratings for CytRx Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx Corp. and related companies with MarketBeat.com's FREE daily email newsletter.